On the stock market since 2020, it operates in the world of real estate. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (-2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
Sales run at $10.4M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 33 buys and 7 sells. Management buying with its own money is usually read as a good sign.
It pays out $2.00 per share each year — regular cash for whoever holds the stock.
A loss of $2.4M against $10.4M in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, MDRRP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MDRRP is a high-risk stock — not yet profitable, and its future rides on its product catching on.